Posted by Michael Wonder on 17 Apr 2023
Agenus receives fast track designation for botensilimab and balstilimab in colorectal cancer
17 April 2023 - Agenus has been granted fast track designation from the US FDA for the investigation of the combination of botensilimab (AGEN1181) and balstilimab (AGEN2034).
The designation is for patients with non-microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer with no active liver involvement.
